HALO Halozyme Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HALO

Price (delayed)

$128.95

Market cap

$14.64B

P/E Ratio

36.22

Dividend/share

N/A

EPS

$3.56

Enterprise value

$16.62B

?
Relative Growth: Rel. Growth: 97
Relative Strength: Rel. Strength: 97
Relative Valuation: Rel. Valuation: 19
Relative Profitability: Rel. Profitability: 92

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE ® drug delivery technology with the ...

Highlights
The company's revenue rose by 41% YoY and by 10% QoQ
HALO's gross profit is up by 38% YoY and by 10% QoQ
HALO's net income is down by 26% year-on-year but it is up by 19% since the previous quarter
HALO's EPS is down by 21% year-on-year but it is up by 20% since the previous quarter
The stock's price to earnings (P/E) is 83% more than its 5-year quarterly average of 19.8 and 72% more than its last 4 quarters average of 21.1
Halozyme Therapeutics's quick ratio has plunged by 69% YoY and by 7% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.halozyme.com
Peers: MNKD LLY BAX PFE

Key stats

What are the main financial stats of HALO

HALO stock price

How has the Halozyme Therapeutics stock price performed over time
Intraday
-1.5%
1 week
0.73%
1 month
17.38%
1 year
97.81%
YTD
91.6%
QTD
16.8%

Financial performance

How have Halozyme Therapeutics's revenue and profit performed over time
Revenue
$1.66B
Gross profit
$1.37B
Operating income
$597.2M
Net income
$413.6M
Gross margin
82.4%
Net margin
24.9%
The net margin has contracted by 47% YoY but it has grown by 8% from the previous quarter
The company's revenue rose by 41% YoY and by 10% QoQ
The operating margin has declined by 38% year-on-year but it is up by 6% since the previous quarter
HALO's gross profit is up by 38% YoY and by 10% QoQ

Price vs fundamentals

How does HALO's price correlate with its fundamentals

Growth

What is Halozyme Therapeutics's growth rate over time

Valuation

What is Halozyme Therapeutics stock price valuation
HALO P/E details
P/E
36.22
P/B
106.55
P/S
9.09
EV/EBIT
27.53
EV/EBITDA
23.13
EV/Sales
9.99
The stock's price to earnings (P/E) is 83% more than its 5-year quarterly average of 19.8 and 72% more than its last 4 quarters average of 21.1
HALO's EPS is down by 21% year-on-year but it is up by 20% since the previous quarter
HALO's price to book (P/B) is 166% higher than its 5-year quarterly average of 40.0 and 53% higher than its last 4 quarters average of 69.6
The company's equity has shrunk by 57% YoY and by 35% QoQ
The price to sales (P/S) is 57% higher than the last 4 quarters average of 5.8 and 18% higher than the 5-year quarterly average of 7.7
The company's revenue rose by 41% YoY and by 10% QoQ

Efficiency

How efficient is Halozyme Therapeutics business performance
The ROE has grown by 43% from the previous quarter and by 32% YoY
HALO's return on sales is down by 40% year-on-year but it is up by 4.9% since the previous quarter
Halozyme Therapeutics's return on assets has decreased by 38% YoY but it has increased by 12% QoQ
HALO's return on invested capital is up by 14% since the previous quarter but it is down by 12% year-on-year

Dividends

What is HALO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HALO.

Financial health

How did Halozyme Therapeutics financials performed over time
The company's total assets is 6% higher than its total liabilities
Halozyme Therapeutics's quick ratio has plunged by 69% YoY and by 7% from the previous quarter
The company's current ratio has shrunk by 68% YoY
The company's equity has shrunk by 57% YoY and by 35% QoQ
Halozyme Therapeutics's debt to equity has soared by 53% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.